However, with further evaluation after his stroke, through the lens of functional assessment, he was
found to have a marked elevation of homocysteine (22 mmoles/liter with normal 6-8 mmoles/liter). He was tested
genetically and found to have a specific genetic uniqueness, homozygous 677C to T polymorphism of MTFHR
(methylenetetrahydrofolate reductase). This SNP (single nucleotide polymorphism) produces a variant enzyme that
requires extraordinarily high doses of folate to facilitate coenzyme binding and MTHFR enzyme activity. His treatment plan
focused on his genetic, proteomic, and metabolomic uniqueness. With appropriate nutrient intervention, his serum
homocysteine equilibrated into the normal range, and he had no further demonstrable progression